**Background of ADAM11 Antibody**
ADAM11 (A Disintegrin and Metalloproteinase 11) is a member of the ADAM family of transmembrane proteins, characterized by a conserved structure comprising a prodomain, metalloproteinase, disintegrin, cysteine-rich, and transmembrane domains. Primarily expressed in the nervous system, ADAM11 plays roles in cell adhesion, proteolytic processing, and signal transduction by mediating interactions between cells or between cells and the extracellular matrix.
Research highlights its involvement in neural development, synaptic plasticity, and tumor suppression. Dysregulation of ADAM11 has been linked to cancers (e.g., breast, lung) and neurological disorders, though its precise mechanisms remain under investigation.
ADAM11 antibodies are critical tools for detecting and studying the protein’s expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to analyze tissue-specific distribution or alterations in disease models. Challenges in ADAM11 antibody development include ensuring specificity due to structural similarities among ADAM family members. Validated antibodies help elucidate ADAM11’s role in physiological and pathological contexts, aiding therapeutic target exploration. Recent studies also explore its potential in modulating cell signaling pathways, such as Notch and EGFR, underscoring its multifaceted biological relevance.